SGLT-2 inhibitors and GLP-1 agonists: First-line therapy for diabetes with established cardiovascular disease.

SGLT-2 inhibitors and GLP-1 agonists: First-line therapy for diabetes with established cardiovascular disease.

Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A

Journal of cardiovascular pharmacology and therapeutics

2019

2019-09

There is a growing body of evidence that diabetes represents a significant and largely modifiable risk factor for cardiovascular disease (CVD). It is known to markedly increase the risk of CVD-with CVD accounting for 2 of every 3 deaths in patients with diabetes. It is suggested that once patients with diabetes develop clinical coronary disease, they have a grim prognosis. In 2008, the Food and Drug Association mandated the evidence of CV safety in any new diabetic therapy, leading to a multitude of large CV outcome trials to assess CV risk from these medications. However, several of these outcome trials with novel antidiabetic therapies have demonstrated not only safety but a clear and definite CV advantage in patients with type 2 diabetes. In this review, we discuss 2 relatively newer classes of diabetic drugs, sodium glucose cotransport 2 inhibitors and glucagon-like peptide 1 agonists, evaluate their efficacy in improving CV outcomes, and discuss the future of CV prevention with these agents.

Humans; Treatment Outcome; Risk Factors; Biomarkers/blood; diabetes; GLP-1 agonists; SGLT-2 inhibitors; Blood Glucose/drug effects/metabolism; Cardiovascular Diseases/blood/diagnosis/mortality/prevention & control; Diabetes Mellitus Type 2/blood/diagnosis/drug therapy/mortality; Glucagon-Like Peptide-1 Receptor/agonists; Incretins/adverse effects/therapeutic use; Sodium-Glucose Transporter 2 Inhibitors/adverse effects/therapeutic use

PMID: 31064213

Copyright © 2019 Elsevier Inc. All rights reserved.

journalArticle

422-427

5

24

1940-4034

NEOMED College of Medicine

Department of Internal Medicine

June2020SubmittedList

Cleveland Clinic Akron General Hospital